Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Marth

Showing results (51-60 of 237) with videos related to

Pageof 24
Sort By:
BMJ Open|April 3, 2024
Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in EuropeJingchuan Zhang, Sneha S Kelkar, Vimalanand S Prabhu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysisMagdalena Steinlechner, Laura Strobel, Katharina Leitner, et al.
American Journal of Obstetrics and Gynecology|November 18, 2004
Interferon-gamma expression is an independent prognostic factor in ovarian cancerChristian Marth, Heidi Fiegl, Alain G Zeimet, et al.
Fetal Diagnosis and Therapy|November 20, 2008
Congenital fibrosarcoma as cause for fetal anemia: prenatal diagnosis and in utero treatmentMatthias Scheier, Angela Ramoni, Alexander Alge, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 26, 2012
Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancerAndreas du Bois, Christian Marth, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 30, 2024
Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysisMagdalena Steinlechner, Laura Strobel, Katharina Leitner, et al.
Acta Obstetricia Et Gynecologica Scandinavica|March 1, 2020
Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancerAnna K Luger, Fabian Steinkohl, Friedrich Aigner, et al.
Cancer Research|January 7, 2006
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancerHeidi Fiegl, Simone Millinger, Georg Goebel, et al.
Advances in Experimental Medicine and Biology|May 29, 2019
Ovarian Cancer Stem Cell HeterogeneityJiri Hatina, Maximilian Boesch, Sieghart Sopper, et al.
Annals of the New York Academy of Sciences|March 8, 2007
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancerDaniel Reimer, Susann Sadr, Annemarie Wiedemair, et al.
Pageof 24

Showing results (51-60 of 237) with videos related to

Sort By:
Pageof 24
BMJ Open|April 3, 2024
Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in EuropeJingchuan Zhang, Sneha S Kelkar, Vimalanand S Prabhu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysisMagdalena Steinlechner, Laura Strobel, Katharina Leitner, et al.
American Journal of Obstetrics and Gynecology|November 18, 2004
Interferon-gamma expression is an independent prognostic factor in ovarian cancerChristian Marth, Heidi Fiegl, Alain G Zeimet, et al.
Fetal Diagnosis and Therapy|November 20, 2008
Congenital fibrosarcoma as cause for fetal anemia: prenatal diagnosis and in utero treatmentMatthias Scheier, Angela Ramoni, Alexander Alge, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 26, 2012
Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancerAndreas du Bois, Christian Marth, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 30, 2024
Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysisMagdalena Steinlechner, Laura Strobel, Katharina Leitner, et al.
Acta Obstetricia Et Gynecologica Scandinavica|March 1, 2020
Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancerAnna K Luger, Fabian Steinkohl, Friedrich Aigner, et al.
Cancer Research|January 7, 2006
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancerHeidi Fiegl, Simone Millinger, Georg Goebel, et al.
Advances in Experimental Medicine and Biology|May 29, 2019
Ovarian Cancer Stem Cell HeterogeneityJiri Hatina, Maximilian Boesch, Sieghart Sopper, et al.
Annals of the New York Academy of Sciences|March 8, 2007
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancerDaniel Reimer, Susann Sadr, Annemarie Wiedemair, et al.
Pageof 24